Searched for
VIATRIS API BUSINESS
Kotak Alt invests Rs 1445 crore for the acquisition of Viatris' API business by Matrix PharmaKotak Alternate Asset Managers has announced a Rs 1,445 crore investment in the acquisition of Viatris' active pharmaceutical ingredient (A...13 Jun, 2024, 07.19 PM IST- Biocon Q4 Results: Net profit drops 57% to Rs 136 croreTotal revenue grew 1% YoY to Rs 3,966 crore. EBITDA for the quarter declined 16% YoY to Rs 964 crore, representing an EBITDA margin of 24% ...16 May, 2024, 10.05 PM IST
- Edelweiss fund to back Matrix Lab founder's buyout of Viatris API bizKotak is lending $150 million (₹1,250 crore) under a mezzanine debt facility to Prasad at 18-20% and arranging an additional $300 million f...30 Apr, 2024, 05.48 AM IST
- Kotak Fund to part finance matrix lab founder's Viatris buyThe fund plans to provide a $150 million mezzanine debt facility at 18-20% and arrange another $300 million from other lenders to finance t...29 Feb, 2024, 05.59 AM IST
- Biocon Q3 Results: PAT at Rs 660 crore vs Rs 42-crore loss a year agoThe company said the revenue growth was supported by income from the divesture of two non-core business assets of Biocon Biologics' branded...08 Feb, 2024, 10.52 PM IST
- Biocon denies plans to sell $1.5 billion generic API businessBiocon API business: Biocon has refuted claims of considering the sale of its generic active pharmaceutical ingredient (API) business, valu...15 Dec, 2023, 01.16 PM IST
- Biocon weighs sale of $1.5 billion generic API businessThe Kiran Mazumdar-Shaw helmed company made a huge bet on biosimilars by acquiring a portfolio of drugs from global drug major Viatris for ...15 Dec, 2023, 10.05 AM IST
- Biocon Q2 Results: Profit zooms 168% YoY to Rs 126 crore; revenue jumps 49%EBITDA for the quarter increased by 68% YoY to Rs 900 crore, representing an EBITDA margin of 25% versus 22% in the same period last year. ...10 Nov, 2023, 06.41 PM IST
- Kotak Fund to invest ₹1,600 crore in Nimmagadda Prasad's API businessKotak Strategic Situations Fund (KSSF) plans to invest around ₹1,600 crore in the active pharmaceutical ingredients (API) business acquired...09 Oct, 2023, 12.36 AM IST
- Matrix Laboratories founder buys back API Biz from ViatrisNimmagadda Prasad, the founder of Matrix Laboratories, has bought back the active pharmaceutical ingredients (API) business he sold to Myla...03 Oct, 2023, 12.56 AM IST
- Matrix Labs founder buys back Viatris' API business in IndiaViatris' latest transaction includes three manufacturing sites and a R&D lab in Hyderabad, three manufacturing sites in Vizag and third-par...02 Oct, 2023, 11.55 PM IST
- Biocon Q1 Results: Profit drops 30% YoY to Rs 101 crore, revenue jumps 59%The company attributed the drop in net profit to depreciation, amortisation and interest increase of Rs 353 crore over last year primarily ...10 Aug, 2023, 10.52 PM IST
- Viatris puts India API business on the blockHowever, the API sale process, which was launched a couple of months ago, has seen no serious buyers, added multiple people aware of the de...30 Mar, 2023, 12.36 AM IST
- Kotak fund invests Rs 1070 crore in BioconEshwar Karra, CEO – Kotak Special Situations Fund at Kotak Investment Advisors said, We are delighted to partner with Biocon and this acqui...22 Feb, 2023, 10.16 PM IST
- Biocon Q2 Results: Net profit drops 66% YoY to Rs 47 cr due to exceptional itemsTotal revenues rose 23% YoY for Q2FY23 at Rs 2,384 crore compared to Rs 1,945 crore in Q2FY2214 Nov, 2022, 10.08 PM IST
- Hold Biocon, target price Rs 380: ICICI DirectBiocon, incorporated in the year 1978, is a Large Cap company (having a market cap of Rs 44314.15 crore) operating in Pharmaceuticals secto...02 May, 2022, 11.18 AM IST
- Market movers: Biocon plunges 11%, Shankara Building jumps 10%When Biocon said it will buy US-based Viatris Inc's biosimilars business in a transaction valued at $3.34 billion that will increase debt o...28 Feb, 2022, 05.46 PM IST
Load More
